Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by FGPstockon Nov 22, 2022 12:03pm
234 Views
Post# 35118969

RE:RE:RE:RE:N-803 had been granted Breakthrough designation. We will too

RE:RE:RE:RE:N-803 had been granted Breakthrough designation. We will too

People should be paid on performance, the stock it at 28c, I am pretty sure your revenue prediction of jan 2023 isn't going to happen. you like to being politics into every discussion when you disagree w someone. You seem like a perfect policticain tho, when something doesn't work, just try to change the sunject or post 101 examples of other companies being bought out. If we all lose our money, the wirting has been on the wall w the failed PP's, multiple CEO's leaving and Dr Vera leaving which you once praised. Keep moving the ball and distracting shareholders w nonsense
<< Previous
Bullboard Posts
Next >>